Nortriptyline/prednisolone

Drug Profile

Nortriptyline/prednisolone

Alternative Names: CRx-170; Prednisolone/nortriptyline - CombinatoRx

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Anti-inflammatories; Dibenzocycloheptenes; Glucocorticoids; Non-opioid analgesics; Pregnadienetriols; Tricyclic antidepressants
  • Mechanism of Action Catecholamine receptor modulators; Glucocorticoid receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Allergic asthma; Pain

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 17 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
  • 17 Jul 2014 Discontinued - Phase-II for Allergic asthma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top